Palisade Bio【PALI】銘柄情報

Palisade Bio Inc (PALI) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

1.73

( -2.81% )

買値

1.72

売値

1.80

出来高

2,182,054

1.69 日の範囲 1.81

0.53 52 週間の範囲 2.855

時価総額

289.644M

前日終値

1.78

始値

1.78

時刻

1.76

最終取引時間

財務取引量

US$ 3,862,554

VWAP

1.7701

平均取引量 (3 か月)

US$ 3,922,974

発行済株式数

167,424,202

配当利回り

PER

-8.21

1 株当たり利益 (EPS)

-0.23

歳入

純利益

-24.15M

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical... Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

www.palisadebio.com

本社

Denver, United States

設立

2026

Palisade Bio Inc is listed in the Healthcare sector of the ナスダック市場 with ticker PALI. The last closing price for Palisade Bio was US$1.78. Over the last year, Palisade Bio shares have traded in a share price range of US$ 0.53 to US$ 2.855.

Palisade Bio currently has 167,424,202 shares in issue. The market capitalisation of Palisade Bio is US$289.64 million. Palisade Bio has a price to earnings ratio (PE ratio) of -8.21.

Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn’s Disease at New York Academy of Sciences Symposium

Presentation to highlight fibrostenotic Crohn’s disease biology and the potential of a locally bioactivated...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.2	-10.3626943005	1.93	1.94	1.64	2314775	1.73628507	CS
4	-0.07	-3.88888888889	1.8	2.155	1.64	2773925	1.89746395	CS
12	-0.25	-12.6262626263	1.98	2.855	1.48	3694738	2.02097467	CS
26	-0.47	-21.3636363636	2.2	2.855	1.45	4128844	1.94509388	CS
52	1.0271	146.12320387	0.7029	2.855	0.53	4774734	1.69902346	CS
156	0.18	11.6129032258	1.55	9.09	0.3602	2346947	1.76311574	CS
260	-2.4	-58.1113801453	4.13	9.09	0.06	2240876	1.77206436	CS